GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
- Conditions
- Interventions
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 239
- Registration Number
- NCT01435044
- Locations
- 🇺🇸
Advanced Research Institute, Trinity, Florida, United States
🇺🇸UCSD Antiviral Research Center, San Diego, California, United States
🇺🇸eStudy Site, San Diego, California, United States
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 163
- Registration Number
- NCT01434498
- Locations
- 🇺🇸
Kaiser Permanente Medical Center, Los Angeles, California, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States
🇺🇸Kaiser Permanente, San Diego, California, United States
Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 82
- Registration Number
- NCT01431898
- Locations
- 🇺🇸
Avail Clinical Research, LLC, Deland, Florida, United States
🇺🇸Impact Clinical Trials, Las Vegas, Nevada, United States
🇺🇸University of Utah Health Sciences Center, Salt Lake City, Utah, United States
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
- Conditions
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 949
- Registration Number
- NCT01425359
- Locations
- 🇷🇺
State Institution of Healthcare Perm Regional Hospital for War Veterans, Perm, Russian Federation
🇺🇸Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
🇺🇸Med-Tech Research, Houston, Texas, United States
Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 61
- Registration Number
- NCT01404234
- Locations
- 🇩🇪
Charite Campus Virchow Klinikum, Berlin, Germany
🇩🇪J.W. Goethe University Hopsital, Frankfurt, Germany
🇫🇷Hopital Necker Enfants Malades, Paris Cedex 15, France
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT01393106
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
- Conditions
- Interventions
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 248
- Registration Number
- NCT01384383
- Locations
- 🇺🇸
Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸North Shore University Hospital, Great Neck, New York, United States
Aztreonam Lysine for Pseudomonas Infection Eradication Study
- Conditions
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 105
- Registration Number
- NCT01375049
- Locations
- 🇺🇸
Nemours Children's Clinic- Jacksonville, Jacksonville, Florida, United States
🇺🇸Nemours Childrens Clinic Orlando, Orlando, Florida, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients
- Conditions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 510
- Registration Number
- NCT01375036
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 163
- Registration Number
- NCT01371578
- Locations
- 🇺🇸
Digestive Healthcare of Georgia, Atlanta, Georgia, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Virginia Mason Medical Center, Digestive Disease Institute, Seattle, Washington, United States